Steppogenin

Research use only, not for human use.

Steppogenin exhibits significant tyrosinase inhibition activity, ;it also shows strong mushroom tyrosinase inhibitory activity with IC(50) values lower than 50 microM, more potent than kojic acid (IC(50) = 71.6 microM), a well-known tyrosinase inhibitor.

Steppogenin exhibits significant tyrosinase inhibition activity, ;it also shows strong mushroom tyrosinase inhibitory activity with IC(50) values lower than 50 microM, more potent than kojic acid (IC(50) = 71.6 microM), a well-known tyrosinase inhibitor.

RT-PCRCell Line:A549 cells Concentration:0, 0.3, 1, 3 μM Incubation Time:6 h Result:Suppressed the mRNA expression of HIF-1α target genes (VEGF, GLUT1, CXCR4, and CA9) under hypoxic conditions.Western Blot Analysis Cell Line:HEK293T, A549, ARPE19 cells Concentration:0, 0.3, 1, 3 μM Incubation Time:16 h Result:Significantly suppressed HIF-1α protein levels in a dose-dependent manner. reduced nuclear expression of HIF-1α under hypoxic conditions. Inhibited protein levels of VEGF, CXCR4, and CA9 compared with the levels detected in the vehicle control group. Suppresseed VEGF-induced DLL4 protein expression.

Pharmacokinetic Parameters of Steppogenin in male C57BL/6 J mice. Animal Model:C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)Dosage:2 mg/kg Administration:IP, once Result:Significantly suppressed tumor growth.Animal Model:C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)Dosage:2 mg/kg Administration:IP, once (Pharmacokinetic Analysis)Result:Showed the highest distribution to the liver and spleen (25.5-fold and 9.74-fold AUC ratio, respectively) with significantly higher T1/2. may not be accumulated even in the highly distributed tissues after the repeated administration of steppogenin.

——

Others

Other Targets

——

——

——

56486-94-3

288.3

C15H12O6

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years